Brief: Irlab Q4 Operating Loss Widens to SEK 22.6 Mln

IRLAB Therapeutics AB

23/02/2022 06:57

Feb 23 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB'S YEAR-END REPORT JANUARY 1 - DECEMBER 31, 2021
    * Q4 NET SALES SEK 12.1 MILLION VERSUS SEK 0 MILLION YEAR
AGO
    * Q4 OPERATING LOSS SEK 22.6 MILLION VERSUS LOSS SEK 19.4
MILLION
YEAR AGO
    * IRLAB IS IN A PHASE THAT REQUIRES THE PRECLINICAL AND
CLINICAL
DEVELOPMENT OF DRUG CANDIDATES TO BE PRIORITIZED, WHICH IS WHY
NO DIVIDEND IS DEEMED TO BE RELEVANT IN THE COMING YEARS. THE
BOARD OF DIRECTORS HAS PROPOSED THAT NO DIVIDEND BE PAID FOR THE
2021 FINANCIAL YEAR

Source text for Eikon:  ID:nMFN9CgJlX 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))